Aardvark Therapeutics, Inc. Common Stock AARD Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $62.44M— | $47.05M— | $39.29M— | —— | —— | ||
| $28.76M— | $62.98M— | $87.07M— | —— | —— | ||
| $10.04M— | $10.96M— | $9.57M— | —— | —— | ||
| $93.58M— | $111.89M— | $129.21M— | —— | —— | ||
| $269K— | $355K— | $439K— | —— | —— | ||
| $4.74M— | $4.94M— | $3.58M— | —— | —— | ||
| $98.59M— | $117.18M— | $133.23M— | —— | —— | ||
| $16.07M+228% | $14.13M+642% | $14.35M— | $9.33M— | $4.9M— | ||
| $6.78M— | $8.04M— | $5.86M— | —— | —— | ||
| $336K— | $441K— | $429K— | —— | —— | ||
| $11.6M— | $10.55M— | $10.74M— | —— | —— | ||
| —— | $0— | $116K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | —— | —— | ||
| $11.6M— | $10.55M— | $10.85M— | —— | —— | ||
| $0— | $0— | $0— | —— | —— | ||
| $0— | $0— | $0— | —— | —— | ||
| $224.48M— | $222.47M— | $220.62M— | —— | —— | ||
| -$137.51M— | -$115.92M— | -$98.32M— | —— | —— | ||
| $14K— | $81K— | $82K— | —— | —— | ||
| $86.99M-42.3% | $106.63M+295% | $122.38M+365% | $136.93M— | $150.69M— | ||
| $98.59M— | $117.18M— | $133.23M— | —— | —— | ||
| $4.74M— | $4.94M— | $3.58M— | —— | —— | ||
| $269K— | $355K— | $439K— | —— | —— | ||
| $269K— | $355K— | $439K— | —— | —— | ||
| $4.74M— | $4.94M— | $3.58M— | —— | —— | ||
| $28.76M— | $62.98M— | $87.07M— | —— | —— | ||
| $269K— | $355K— | $439K— | —— | —— | ||
| $4.74M— | $4.94M— | $3.58M— | —— | —— | ||
| $6.78M— | $8.04M— | $5.86M— | —— | —— | ||
| $6.78M— | $8.04M— | $5.86M— | —— | —— | ||
| $336K— | $441K— | $545K— | —— | —— | ||
| $224.48M— | $222.47M— | $220.62M— | —— | —— | ||
| $0— | $0— | $0— | —— | —— | ||
| $0— | $0— | $0— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aardvark Therapeutics, Inc. Common Stock's total assets?
- Aardvark Therapeutics, Inc. Common Stock (AARD) holds $98.6M in total assets, down 37.2% year over year.
- How much debt does Aardvark Therapeutics, Inc. Common Stock have?
- Aardvark Therapeutics, Inc. Common Stock carries $336.0K in total debt against $87.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Aardvark Therapeutics, Inc. Common Stock have?
- Aardvark Therapeutics, Inc. Common Stock holds $62.4M in cash and equivalents.
- Can Aardvark Therapeutics, Inc. Common Stock cover its short-term obligations?
- Its current ratio is 8.06 — current assets exceed current liabilities.
- Where does Aardvark Therapeutics, Inc. Common Stock's balance sheet data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.